These findings suggest that TEs reexpression whether spontaneous (in IBCs with PIWIL2–PIWIL4 downregulation) or induced under epigenetic therapy using hypomethylating agents has important potential clinical implications for cancer immunotherapy [53,61,63]. This evidence concerns the gene PIWIL4 and cancer.